A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Crohn's Disease

In brief

REMICADE (infliximab) is a drug used to treat active Crohn's disease and is being tested in an experiment to see if it may be useful in preventing relapse of Crohn's disease after surgical resection. This study will compare the effects (both good and bad) of REMICADE (infliximab) to those of placebo. Placebo looks like the drug being studied but has no active ingredients.

Key facts

Study ID

NCT01190839

Run by

Janssen Biotech, Inc.

People needed

297

Starts

2010-11-01

Expected to finish

2014-12-01

Last updated by the study team

2016-02-04

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a documented diagnosis of CD confirmed by endoscopic, histologic and/or radiologic studies prior to resection or by tissue obtained at resection
• Have undergone an ileocolonic surgical resection
• Patients must also be at an increased risk of recurrence of active CD
• Patients must not have previously discontinued infliximab as a result of tolerability issues or they must be naive to treatment with infliximab. Provided patients meet the above criteria pertaining to infliximab, they are eligible to enroll if they received prior treatment with adalimumab and/or certolizumab
• Patients must undergo screening for HBV
• Baseline CDAI < 200
• Have adequate blood and liver test values

You may not qualify if…

• Have a history of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, prior to screening
• Have a chest radiograph within 3 months prior to the first infusion of study agent that shows a clinically significant abnormality, such as a malignancy or infection, or any abnormalities suggestive of TB
• Have macroscopically active CD which was not resected at the time of surgery
• Do not meet the criteria for being at an increased risk of postoperative recurrence of active CD as outlined in the inclusion criteria
• Have evidence of an active infection at the time of randomization or have had a serious infection not related to CD (e.g., hepatitis, pneumonia, or pyelonephritis), within 6 months prior to screening
• Have or have had an opportunistic infection (e.g., herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening
• Have any known malignancy or history of malignancy within the 5-year period prior to screening (with the exception of squamous or basal cell carcinoma of the skin that has been completely excised without evidence of recurrence)
• Have any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements.

Where it is running

• Study site — La Jolla, California, United States
• Study site — Orange, California, United States
• Study site — Redwood City, California, United States
• Study site — San Diego, California, United States
• Study site — Littleton, Colorado, United States
• Study site — Glastonbury, Connecticut, United States
• Study site — Middletown, Connecticut, United States
• Study site — New Haven, Connecticut, United States
• Study site — Gainesville, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Naples, Florida, United States
• Study site — Weston, Florida, United States
• Study site — Winter Park, Florida, United States
• Study site — Decatur, Georgia, United States
• Study site — Macon, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Clive, Iowa, United States
• Study site — Iowa City, Iowa, United States
• Study site — Lexington, Kentucky, United States
• Study site — Louisville, Kentucky, United States
• Study site — Baton Rouge, Louisiana, United States
• Study site — New Orleans, Louisiana, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.